Genentech announces positive results for crovalimab in PNH
A subcutaneous injection every 4 weeks of crovalimab, a novel, investigational anti-C5 recycling monoclonal antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not been previously treated with complement inhibitors achieved disease control and was non-inferior to eculizumab, in the global Phase III COMMODORE 2 study, according to a press release by Genentech.
Eculizumab, the current standard of care, is administered intravenously every 2 weeks.
“People with PNH may benefit from more options to achieve robust disease control with less frequent treatment intervals,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development in the press release. “As the first global Phase III data for crovalimab, these results emphasize its potential to address these needs. We look forward to submitting these data to regulatory authorities, bringing us one step closer to making crovalimab available for people with PNH around the world.”
Read the full press release here.